2611005629
  • Open Access
  • Article

Distinct Skeletal Muscle Proteomic Profiles after Single and Repeated Intermittent Clenbuterol Administration in Mice

  • Keisuke Hitachi 1,*,   
  • Hisateru Yamaguchi 2,3,   
  • Yuri Kiyofuji 1 and 
  • Kunihiro Tsuchida 1,*

Received: 26 July 2026 | Revised: 08 October 2026 | Accepted: 10 November 2026 | Published: 17 November 2026

Abstract

Clenbuterol (CB), a β2-adrenergic receptor agonist, is known to increase skeletal muscle mass, but the proteomic changes associated with repeated intermittent CB administration remain poorly characterized. We compared plantaris muscle proteomes from mice receiving CB only during the final 2-week treatment period (single CB) or during three 2-week periods separated by 4-week washout intervals (repeated CB), along with untreated controls. Label-free quantitative proteomics identified 49 and 74 differentially abundant proteins in the single and repeated CB groups, respectively, relative to controls, and 32 proteins differed between the two CB-treated groups. Functional enrichment analysis of these protein sets identified terms related to lipid metabolism in the single CB group, muscle structure and intracellular protein transport in the repeated CB group, and muscle contraction and endosomal transport in the direct comparison between the CB-treated groups. The differentially abundant proteins were further classified according to their abundance patterns, including sustained, reinforced, and repeated-specific response classes. Immunoblotting showed increases in Klhl40 and Napa (sustained class) and Galectin-3 (reinforced class) in both CB-treated groups, whereas Rab18 (repeated-specific class) was significantly increased relative to controls only in the repeated CB group. Together, these findings indicate that single and repeated CB treatments were associated with overlapping but distinct skeletal muscle proteomic profiles, providing a foundation for future studies of the effects of CB administration regimens and prior exposure.

References 

  • 1.

    Lynch, G.S.; Ryall, J.G. Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease. Physiol. Rev. 2008, 88, 729–767. https://doi.org/10.1152/physrev.00028.2007.

  • 2.

    Hostrup, M.; Onslev, J. The Beta2-adrenergic Receptor—A Re-emerging Target to Combat Obesity and Induce Leanness? J. Physiol. 2022, 600, 1209–1227. https://doi.org/10.1113/jp281819.

  • 3.

    Reeds, P.J.; Hay, S.M.; Dorward, P.M.; et al. The Effect of β-Agonists and Antagonists on Muscle Growth and Body Composition of Young Rats (Rattus Sp.). Comp. Biochem. Physiol. Part C: Comp. Pharmacol. 1988, 89, 337–341. https://doi.org/10.1016/0742-8413(88)90234-4.

  • 4.

    Hinkle, R.T.; Hodge, K.M.B.; Cody, D.B.; et al. Skeletal Muscle Hypertrophy and Anti-atrophy Effects of Clenbuterol Are Mediated by the β2-adrenergic Receptor. Muscle Nerve 2002, 25, 729–734. https://doi.org/10.1002/mus.10092.

  • 5.

    Ryall, J.G.; Sillence, M.N.; Lynch, G.S. Systemic Administration of β2-adrenoceptor Agonists, Formoterol and Salmeterol, Elicit Skeletal Muscle Hypertrophy in Rats at Micromolar Doses. Br. J. Pharmacol. 2006, 147, 587–595. https://doi.org/10.1038/sj.bjp.0706669.

  • 6.

    Meister, J.; Bone, D.B.J.; Knudsen, J.R.; et al. Clenbuterol Exerts Antidiabetic Activity through Metabolic Reprogramming of Skeletal Muscle Cells. Nat. Commun. 2022, 13, 22. https://doi.org/10.1038/s41467-021-27540-w.

  • 7.

    Kim, J.; Grotegut, C.A.; Wisler, J.W.; et al. β-Arrestin 1 Regulates β2-Adrenergic Receptor-Mediated Skeletal Muscle Hypertrophy and Contractility. Skelet. Muscle 2018, 8, 39. https://doi.org/10.1186/s13395-018-0184-8.

  • 8.

    Burniston, J.G.; Clark, W.A.; Tan, L.; et al. Dose-dependent Separation of the Hypertrophic and Myotoxic Effects of the β2-adrenergic Receptor Agonist Clenbuterol in Rat Striated Muscles. Muscle Nerve 2006, 33, 655–663. https://doi.org/10.1002/mus.20504.

  • 9.

    Rothwell, N.J.; Stock, M.J.; Sudera, D.K. Changes in Tissue Blood Flow and β-receptor Density of Skeletal Muscle in Rats Treated with the β2-adrenoceptor Agonist Clenbuterol. Br. J. Pharmacol. 1987, 90, 601–607. https://doi.org/10.1111/j.1476-5381.1987.tb11211.x.

  • 10.

    Sato, S.; Nomura, S.; Kawano, F.; et al. Adaptive Effects of the β2-Agonist Clenbuterol on Expression of β2-Adrenoceptor mRNA in Rat Fast-Twitch Fiber-Rich Muscles. J. Physiol. Sci. 2010, 60, 119–127. https://doi.org/10.1007/s12576-009-0075-1.

  • 11.

    Guddat, S.; Fußhöller, G.; Geyer, H.; et al. Clenbuterol—Regional Food Contamination a Possible Source for Inadvertent Doping in Sports. Drug Test. Anal. 2012, 4, 534–538. https://doi.org/10.1002/dta.1330.

  • 12.

    Thevis, M.; Geyer, L.; Geyer, H.; et al. Adverse Analytical Findings with Clenbuterol among U-17 Soccer Players Attributed to Food Contamination Issues. Drug Test. Anal. 2013, 5, 372–376. https://doi.org/10.1002/dta.1471.

  • 13.

    Parr, M.K.; Blokland, M.H.; Liebetrau, F.; et al. Distinction of Clenbuterol Intake from Drug or Contaminated Food of Animal Origin in a Controlled Administration Trial—The Potential of Enantiomeric Separation for Doping Control Analysis. Food Addit. Contam.: Part A 2017, 34, 525–535. https://doi.org/10.1080/19440049.2016.1242169.

  • 14.

    Spiller, H.A.; James, K.J.; Scholzen, S.; et al. A Descriptive Study of Adverse Events from Clenbuterol Misuse and Abuse for Weight Loss and Bodybuilding. Subst. Abus. 2013, 34, 306–312. https://doi.org/10.1080/08897077.2013.772083.

  • 15.

    Grimmer, N.M.; Gimbar, R.P.; Bursua, A.; et al. Rhabdomyolysis Secondary to Clenbuterol Use and Exercise. J. Emerg. Med. 2016, 50, e71–e74. https://doi.org/10.1016/j.jemermed.2015.09.006.

  • 16.

    Burniston, J.G.; McLean, L.; Beynon, R.J.; et al. Anabolic Effects of a Non-myotoxic Dose of the β2-adrenergic Receptor Agonist Clenbuterol on Rat Plantaris Muscle. Muscle Nerve 2007, 35, 217–223. https://doi.org/10.1002/mus.20684.

  • 17.

    Jessen, S.; Prats Quesada, J.; Di Credico, A.; et al. Beta2-Adrenergic Stimulation Induces Resistance Training-Like Adaptations in Human Skeletal Muscle: Potential Role of KLHL41. Scand. J. Med. Sci. Sports 2024, 34, e14736. https://doi.org/10.1111/sms.14736.

  • 18.

    Kim, K.H.; Kim, Y.S.; Yang, J. The Muscle-hypertrophic Effect of Clenbuterol Is Additive to the Hypertrophic Effect of Myostatin Suppression. Muscle Nerve 2011, 43, 700–707. https://doi.org/10.1002/mus.21950.

  • 19.

    Hitachi, K.; Yamaguchi, H.; Tsuchida, K. Proteomic Analysis Data of Skeletal Muscle Tissue in Myosin Heavy Chain -IIx and -IIb Double Knockout Mice. J. Proteome Data Methods 2025, 7, 2. https://doi.org/10.14889/jpdm.2025.0002.

  • 20.

    Hitachi, K.; Kiyofuji, Y.; Yamaguchi, H.; et al. Simultaneous Loss of Skeletal Muscle Myosin Heavy Chain IIx and IIb Causes Severe Skeletal Muscle Hypoplasia in Postnatal Mice. FASEB J. 2023, 37, e22692. https://doi.org/10.1096/fj.202200581r.

  • 21.

    Hughes, C.S.; Moggridge, S.; Müller, T.; et al. Single-Pot, Solid-Phase-Enhanced Sample Preparation for Proteomics Experiments. Nat. Protoc. 2019, 14, 68–85. https://doi.org/10.1038/s41596-018-0082-x.

  • 22.

    Tyanova, S.; Temu, T.; Sinitcyn, P.; et al. The Perseus Computational Platform for Comprehensive Analysis of (Prote)Omics Data. Nat. Methods 2016, 13, 731–740. https://doi.org/10.1038/nmeth.3901.

  • 23.

    Zhou, Y.; Zhou, B.; Pache, L.; et al. Metascape Provides a Biologist-Oriented Resource for the Analysis of Systems-Level Datasets. Nat. Commun. 2019, 10, 1523. https://doi.org/10.1038/s41467-019-09234-6.

  • 24.

    Hostrup, M.; Moesgaard, L.; Thomassen, M.; et al. Clenbuterol, but Not Inhaled Formoterol, Upregulates the Sarcomere Stabilizer KLHL41 to a Similar Extent as Resistance Training in Human Skeletal Muscle. Drug Test. Anal. 2026, 18, 66–73. https://doi.org/10.1002/dta.3963.

  • 25.

    Garg, A.; O’Rourke, J.; Long, C.; et al. KLHL40 Deficiency Destabilizes Thin Filament Proteins and Promotes Nemaline Myopathy. J. Clin. Investig. 2014, 124, 3529–3539. https://doi.org/10.1172/jci74994.

  • 26.

    Johannes, L.; Jacob, R.; Leffler, H. Galectins at a Glance. J. Cell Sci. 2018, 131, jcs208884. https://doi.org/10.1242/jcs.208884.

  • 27.

    Cerri, D.G.; Rodrigues, L.C.; Alves, V.M.; et al. Endogenous Galectin-3 Is Required for Skeletal Muscle Repair. Glycobiology 2021, 31, 1295–1307. https://doi.org/10.1093/glycob/cwab071.

  • 28.

    Brightwell, C.R.; Latham, C.M.; Thomas, N.T.; et al. A Glitch in the Matrix: The Pivotal Role for Extracellular Matrix Remodeling during Muscle Hypertrophy. Am. J. Physiol.-Cell Physiol. 2022, 323, C763–C771. https://doi.org/10.1152/ajpcell.00200.2022.

  • 29.

    Hay, J.C.; Scheller, R.H. SNAREs and NSF in Targeted Membrane Fusion. Curr. Opin. Cell Biol. 1997, 9, 505–512. https://doi.org/10.1016/s0955-0674(97)80026-9.

  • 30.

    Ryu, J.-K.; Min, D.; Rah, S.-H.; et al. Spring-Loaded Unraveling of a Single SNARE Complex by NSF in One Round of ATP Turnover. Science 2015, 347, 1485–1489. https://doi.org/10.1126/science.aaa5267.

  • 31.

    Ozeki, S.; Cheng, J.; Tauchi-Sato, K.; et al. Rab18 Localizes to Lipid Droplets and Induces Their Close Apposition to the Endoplasmic Reticulum-Derived Membrane. J. Cell Sci. 2005, 118, 2601–2611. https://doi.org/10.1242/jcs.02401.

  • 32.

    Xu, D.; Li, Y.; Wu, L.; et al. Rab18 Promotes Lipid Droplet (LD) Growth by Tethering the ER to LDs through SNARE and NRZ Interactions. J. Cell Biol. 2018, 217, 975–995. https://doi.org/10.1083/jcb.201704184.

  • 33.

    Jessen, S.; Di Credico, A.; Moreno-Justicia, R.; et al. Fibre Type–Specific Proteomics Reveals Shared and Distinct Skeletal Muscle Adaptations to Resistance Training and Beta2-Adrenergic Agonist. J. Cachexia, Sarcopenia Muscle 2026, 17, e70175. https://doi.org/10.1002/jcsm.70175.

  • 34.

    Deutsch, E.W.; Csordas, A.; Sun, Z.; et al. The ProteomeXchange Consortium in 2017: Supporting the Cultural Change in Proteomics Public Data Deposition. Nucleic Acids Res. 2017, 45, D1100–D1106. https://doi.org/10.1093/nar/gkw936.

  • 35.

    Okuda, S.; Watanabe, Y.; Moriya, Y.; Kawano, S.; Yamamoto, T.; Matsumoto, M.; Takami, T.; Kobayashi, D.; Araki, N.; Yoshizawa, A.C.; et al. jPOSTrepo: An International Standard Data Repository for Proteomes. Nucleic Acids Res. 2017, 45, D1107–D1111. https://doi.org/10.1093/nar/gkw1080.

Share this article:
How to Cite
Hitachi, K.; Yamaguchi, H.; Kiyofuji, Y.; Tsuchida, K. Distinct Skeletal Muscle Proteomic Profiles after Single and Repeated Intermittent Clenbuterol Administration in Mice. Proteomic Science 2026, 1 (1), 3.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.
Article Metrics
55
Article Views
0
Citations